SCHEMBL4679149

SCHEMBL4679149

O=C(Cc1nc(Cc2cccc(F)c2)cs1)C(=O)c1nn[nH]n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
FFAR2 O15552 2/20 0.39
KDM4E B2RXH2 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HCAR2 Q8TDS4 1/20 0.37
PIN1 Q13526 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
PRKACA P17612 1/20 0.34
ROCK1 Q13464 1/20 0.34
GLS O94925 1/20 0.34
MPO P05164 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
GPR52 Q9Y2T5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676194 0.92 HDAC1 (0.43) HDAC1HDAC6FFAR2KDM4ESMN1; SMN2
SCHEMBL4675556 0.88 HDAC6 (0.39) HDAC1HDAC6KDM4ESMN1; SMN2PIN1
SCHEMBL4671627 0.87 HDAC1 (0.42) HDAC1HDAC6SMN1; SMN2KMT2ACES1
SCHEMBL4678623 0.84 HDAC1 (0.43) HDAC1HDAC6KDM4ESMN1; SMN2HCAR2
SCHEMBL4677732 0.82 HDAC1 (0.32) HDAC1HDAC6FFAR2SMN1; SMN2KMT2A
SCHEMBL4677642 0.82 FFAR2 (0.40) FFAR2HCAR2PIN1PTGDR2PRKACA
SCHEMBL4673601 0.82 LMNA (0.36) SMN1; SMN2PTGDR2PRKACAROCK1GLS
SCHEMBL4672521 0.82 FFAR2 (0.40) FFAR2HCAR2PIN1PTGDR2PRKACA
SCHEMBL4675014 0.81 HDAC1 (0.39) HDAC1HDAC6CACNA1GCACNA1HCACNA1I
SCHEMBL4679324 0.81 ALDH1A1 (0.39) HDAC1HDAC6SMN1; SMN2PTGDR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HDAC1 250/4885HDAC6 1000/4885FFAR2 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.